|
|
 |
|
Viewing report
|
|
|
|
Bayer AG: PharmaVitae Profile
Datamonitor, June 2010
This analysis examines the historical and forecast performance for Bayer in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Scope:
- Gain insight into Bayer's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and sources
- Strategic insight into the prospects for Bayer over the next six years.
Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Reasons to buy:
- Benchmark Bayer's performance against key rivals in the prescription pharmaceutical sector
- Analyse how Bayer's acquisition of Schering AG in 2006 has notably enhanced the company's HealthCare division
- Assess how an increased healthcare focus and merger-related synergies will drive an increase in operating profit
|
|
|
|
